# A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Source: https://onco.cc/trials/nct07208149/  
OnCo record `nct07208149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MCLA-129 in triple-negative breast cancer, run by Shenzhen Majory Biotechnology Co., Ltd., now recruiting.

## Summary

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) is a phase 1/2 interventional study registered as NCT07208149 by Shenzhen Majory Biotechnology Co., Ltd., with 42 participants planned, started 2026-01-29 and due to reach its primary completion in 2028-09-01. Interventions recorded: MR001 Bispecific Antibody for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07208149
- Phase: 1/2
- Setting: A Phase Ib/IIa, Open-Label, Two-Cohort, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) Who Have Progressed After First-Line or Later-Line Therapy
- Sponsor: Shenzhen Majory Biotechnology Co., Ltd.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07208149: https://clinicaltrials.gov/study/NCT07208149

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [MCLA-129](https://onco.cc/drugs/mcla-129/)

---
JSON: https://onco.cc/api/v1/entities/nct07208149.json